Shield Therapeutics (STX) Panoramica del titolo
Shield Therapeutics plc, azienda farmaceutica specializzata in fase commerciale, si concentra sulla commercializzazione di farmaci per il trattamento di esigenze mediche insoddisfatte. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 1/6 |
| Dividendi | 0/6 |
STX Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Shield Therapeutics plc
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | UK£0.064 |
| Massimo di 52 settimane | UK£0.13 |
| Minimo di 52 settimane | UK£0.022 |
| Beta | 1.88 |
| Variazione di 1 mese | -33.16% |
| Variazione a 3 mesi | -34.20% |
| Variazione di 1 anno | 159.18% |
| Variazione a 3 anni | -5.22% |
| Variazione a 5 anni | -88.86% |
| Variazione dall'IPO | -95.96% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • May 04
STX: Pediatric And Asia Expansion Will Drive Future Earnings Upside
Analysts have adjusted their price target on Shield Therapeutics to £0.14 per share, with the change linked to updated assumptions that maintain the fair value level while recalibrating revenue growth, profit margin and future P/E expectations. What's in the News Partner MEDLEAP Pharma enrolled the first patient in a Phase II clinical trial in Japan testing ACCRUFeR (ferric maltol) as a potential treatment for pulmonary arterial hypertension, following prior confirmation of the development plan by Japan's Pharmaceuticals and Medical Devices Agency (Product-Related Announcement).Aggiornamento della narrazione • Apr 18
STX: Expanded Pediatric Reach And China Entry Will Support Stronger Future Earnings
Analysts have trimmed their fair value estimate for Shield Therapeutics to £0.14 per share, citing updated assumptions that combine a lower revenue growth outlook with a higher projected profit margin and a reduced future P/E multiple. What's in the News EMA's Committee for Medicinal Products for Human Use issued a positive opinion to extend FeRACCRU's indication to include adolescents, so it is now indicated for iron deficiency in adults and pediatric patients 12 years and older in Europe, with all measures in the agreed Pediatric Investigation Plan confirmed as fulfilled (Key Developments).Articolo di analisi • Apr 12
Shield Therapeutics plc (LON:STX) Released Earnings Last Week And Analysts Lifted Their Price Target To UK£0.17
It's been a good week for Shield Therapeutics plc ( LON:STX ) shareholders, because the company has just released its...Recent updates
Aggiornamento della narrazione • May 04
STX: Pediatric And Asia Expansion Will Drive Future Earnings Upside
Analysts have adjusted their price target on Shield Therapeutics to £0.14 per share, with the change linked to updated assumptions that maintain the fair value level while recalibrating revenue growth, profit margin and future P/E expectations. What's in the News Partner MEDLEAP Pharma enrolled the first patient in a Phase II clinical trial in Japan testing ACCRUFeR (ferric maltol) as a potential treatment for pulmonary arterial hypertension, following prior confirmation of the development plan by Japan's Pharmaceuticals and Medical Devices Agency (Product-Related Announcement).Aggiornamento della narrazione • Apr 18
STX: Expanded Pediatric Reach And China Entry Will Support Stronger Future Earnings
Analysts have trimmed their fair value estimate for Shield Therapeutics to £0.14 per share, citing updated assumptions that combine a lower revenue growth outlook with a higher projected profit margin and a reduced future P/E multiple. What's in the News EMA's Committee for Medicinal Products for Human Use issued a positive opinion to extend FeRACCRU's indication to include adolescents, so it is now indicated for iron deficiency in adults and pediatric patients 12 years and older in Europe, with all measures in the agreed Pediatric Investigation Plan confirmed as fulfilled (Key Developments).Articolo di analisi • Apr 12
Shield Therapeutics plc (LON:STX) Released Earnings Last Week And Analysts Lifted Their Price Target To UK£0.17
It's been a good week for Shield Therapeutics plc ( LON:STX ) shareholders, because the company has just released its...Aggiornamento della narrazione • Apr 03
STX: Pediatric And China Approvals Will Expand Future Earnings Power
Analysts have maintained their fair value estimate for Shield Therapeutics at £0.14. The discount rate remains unchanged, and updated assumptions for revenue growth, profit margin and future P/E support the latest price target view.
Aggiornamento della narrazione • Mar 20
STX: Pediatric Label Expansion And Added Exclusivity Will Support Future Upside
Analysts have kept their fair value framework for Shield Therapeutics broadly unchanged, with a slightly adjusted profit margin outlook and future P/E assumption. These updates feed into a refreshed price target in £ terms that remains closely aligned with the prior figure.Aggiornamento della narrazione • Mar 06
STX: Pediatric Expansion And China Filing Will Redefine Earnings Power
Analysts have lifted their price target for Shield Therapeutics to £0.14 from £0.10, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E that they view as better aligned with the company’s current outlook. What's in the News Shield Therapeutics filed and received acceptance of a Marketing Authorisation Application for ACCRUFeR with China’s National Medical Products Administration for adults with iron deficiency, supported by prior US FDA data and a Phase 3 study in Chinese adults with iron deficiency anemia and inflammatory bowel disease who are intolerant to oral ferrous products (Key Developments).Aggiornamento della narrazione • Feb 19
STX: Pediatric Expansion And Extended Exclusivity Will Support Future Upside Potential
Analysts have kept their fair value estimate for Shield Therapeutics broadly steady at £0.17 per share, reflecting only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that they see as refinements rather than a change in thesis. What's in the News The FDA approved an extension of the indication for ACCRUFeR (ferric maltol) to treat iron deficiency in adult and pediatric patients 10 years and older, following a priority review supported by a Phase 3 pediatric trial in children from 1 month of age with iron deficiency anemia (Key Developments).Aggiornamento della narrazione • Feb 05
STX: Expanded Pediatric Indications And New Market Approvals Will Drive Upside
Analysts have nudged their price target for Shield Therapeutics slightly higher, reflecting small adjustments to revenue growth, profit margin expectations, and the implied future P/E multiple. What's in the News Shield Therapeutics issued earnings guidance for 2026, indicating that it expects to deliver an operating profit in that year (company guidance).Aggiornamento della narrazione • Jan 22
STX: Pediatric Expansion And New Market Approvals Will Support Future Upside
Analysts have lifted their price target on Shield Therapeutics from £0.16 to about £0.17, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What’s in the News US FDA grants priority review approval to extend ACCRUFeR’s indication to adolescents, covering iron deficiency treatment in patients 10 years and older, backed by positive Phase 3 pediatric trial data (FORTIS/ST10-01-305) (Key Developments).Aggiornamento della narrazione • Jan 07
STX: Expanded Pediatric And Global Approvals Will Support Future Upside
Analysts have trimmed their price target on Shield Therapeutics slightly, citing updated expectations for revenue growth of about 41.81%, a lower projected profit margin of around 13.33% and a higher future P/E of roughly 17.49x. Together, these factors imply less upside potential from current levels in cash terms than previously estimated.Aggiornamento della narrazione • Dec 18
STX: Future US Label Expansion Could Still Leave Shares Vulnerable
Analysts have raised their price target for Shield Therapeutics from 0.03 dollars to 0.10 dollars, citing slightly stronger long term revenue growth expectations, while applying a higher discount rate and more conservative profit margin and valuation multiples. What's in the News Presentation of pediatric FORTIS PK sub study at the American Society of Hematology conference in December 2025 showed ferric maltol is well absorbed across pediatric age groups, with maltol rapidly metabolized and excreted, supporting its suitability for iron replacement in children and adolescents (company announcement).Aggiornamento della narrazione • Dec 04
STX: New Regulatory Approvals And Pediatric Data Will Drive Future Upside
Analysts have modestly increased their price target on Shield Therapeutics, citing slightly stronger projected revenue growth, a marginally lower profit margin, and a modestly higher future price-to-earnings multiple. What's in the News The Korean Ministry of Food and Drug Safety granted regulatory approval for ACCRUFeR (ferric maltol) in adults with iron deficiency, opening a new commercial market and triggering eligibility for milestones and royalties (company announcement).Articolo di analisi • Nov 25
Shield Therapeutics plc's (LON:STX) Subdued P/S Might Signal An Opportunity
With a median price-to-sales (or "P/S") ratio of close to 2.6x in the Pharmaceuticals industry in the United Kingdom...Aggiornamento della narrazione • Nov 20
STX: FDA Priority Review and Regulatory Approvals Will Drive Significant Upside
Analysts have modestly raised their price target for Shield Therapeutics from $0.16 to $0.16 per share. This change reflects updated assumptions around discount rates and profit margins, while maintaining a cautiously optimistic outlook.Aggiornamento della narrazione • Nov 06
STX: Upcoming FDA Decision Will Drive Confidence After Positive Pediatric Results
Analysts have maintained their price target for Shield Therapeutics at $0.16, citing stable projections in key financial metrics, including revenue growth and profit margin improvements, as justification for the unchanged valuation. What's in the News Positive efficacy, tolerability, and palatability results for the ferric maltol pediatric FORTIS clinical trial were presented at the American Association of Pediatrics National Conference.Aggiornamento della narrazione • Oct 22
Analysts Maintain Target for Shield Therapeutics Amid Positive Clinical News and Stable Valuation Metrics
Narrative Update on Shield Therapeutics: Analyst Price Target Revision Analysts have maintained their price target for Shield Therapeutics at £0.16. This reflects confidence in the company's prospects, given stable fair value estimates and consistent growth expectations.Aggiornamento della narrazione • Oct 08
Global Aging Trends And Early Detection Will Unlock Markets
Analysts have raised their price target on Shield Therapeutics from $0.14 to $0.16 per share, citing improved profit margin expectations and a steady long-term outlook, despite minor adjustments to growth forecasts. What's in the News Positive efficacy, tolerability, and palatability results for ferric maltol pediatric FORTIS clinical trial were presented at the AAP National Conference, showing significant hemoglobin improvements with no serious adverse events reported (Key Developments).Articolo di analisi • Aug 23
The Market Lifts Shield Therapeutics plc (LON:STX) Shares 76% But It Can Do More
Despite an already strong run, Shield Therapeutics plc ( LON:STX ) shares have been powering on, with a gain of 76% in...Nuova narrazione • Aug 03
Global Aging Trends And Early Detection Will Unlock Markets
An expanding addressable market and greater screening activity are driving strong prescription growth and recurring revenues for Shield's main product.Articolo di analisi • Jun 28
Shield Therapeutics plc (LON:STX) Soars 27% But It's A Story Of Risk Vs Reward
Shield Therapeutics plc ( LON:STX ) shares have had a really impressive month, gaining 27% after a shaky period...Articolo di analisi • Feb 06
Even With A 26% Surge, Cautious Investors Are Not Rewarding Shield Therapeutics plc's (LON:STX) Performance Completely
Shield Therapeutics plc ( LON:STX ) shareholders have had their patience rewarded with a 26% share price jump in the...Articolo di analisi • Oct 30
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Shield Therapeutics plc ( LON:STX ) share price has softened a substantial 28% over the previous 30 days, handing...Articolo di analisi • Oct 12
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Aug 01
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Despite an already strong run, Shield Therapeutics plc ( LON:STX ) shares have been powering on, with a gain of 44% in...Articolo di analisi • Jun 13
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Key Insights Shield Therapeutics will host its Annual General Meeting on 20th of June CEO Greg Madison's total...Articolo di analisi • May 22
Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
Shield Therapeutics plc ( LON:STX ) shareholders are no doubt pleased to see that the share price has bounced 35% in...Rendimenti per gli azionisti
| STX | GB Pharmaceuticals | GB Mercato | |
|---|---|---|---|
| 7D | -7.3% | 2.2% | 0.3% |
| 1Y | 159.2% | 26.1% | 18.8% |
Ritorno vs Industria: STX ha superato il UK Pharmaceuticals che ha restituito 26.1 % nell'ultimo anno.
Rendimento vs Mercato: STX ha superato il mercato UK che ha restituito 18.8 % nell'ultimo anno.
Volatilità dei prezzi
| STX volatility | |
|---|---|
| STX Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 11.9% |
| 10% least volatile stocks in GB Market | 3.1% |
Prezzo delle azioni stabile: STX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato UK.
Volatilità nel tempo: La volatilità settimanale ( 8% ) di STX è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2008 | 63 | Anders Lundstrom | www.shieldtherapeutics.com |
Shield Therapeutics plc, società farmaceutica specializzata in fase commerciale, si concentra sulla commercializzazione di prodotti farmaceutici per il trattamento di esigenze mediche insoddisfatte. Il suo prodotto di punta è Accrufer/Feraccru, una terapia orale non salina per adulti per il trattamento della carenza di ferro con o senza anemia. Shield Therapeutics plc è stata costituita nel 2008 e ha sede a Gateshead, nel Regno Unito.
Shield Therapeutics plc Riepilogo dei fondamenti
| STX statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | UK£67.84m |
| Utili (TTM) | -UK£13.14m |
| Ricavi(TTM) | UK£36.99m |
1.8x
Rapporto P/S-5.2x
Rapporto P/ESTX è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| STX Conto economico (TTM) | |
|---|---|
| Ricavi | US$49.70m |
| Costo del fatturato | US$26.66m |
| Profitto lordo | US$23.04m |
| Altre spese | US$40.69m |
| Utili | -US$17.65m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.017 |
| Margine lordo | 46.36% |
| Margine di profitto netto | -35.52% |
| Rapporto debito/patrimonio netto | -199.9% |
Come si è comportato STX nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 14:02 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Shield Therapeutics plc è coperta da 10 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Howard Miller | Canaccord Genuity |
| Mark Brewer | Cavendish |
| Michael Mitchell | Cavendish |